9003: pass the exams, not just read the notes
Your complete guide to University of Canberra's clinical therapeutics 1 unit. See where the marks are, work real practice questions, and study with an AI tutor that knows 9003.
Sia generates 9003 practice questions, walks through cardiovascular disorders and endocrine disorders step by step, and quizzes you on the material the exam weights most heavily.
Worked example
A patient with confirmed Helicobacter pylori peptic ulcer disease has a documented penicillin (amoxicillin) hypersensitivity. According to the Australian first-line approach taught in this unit, which eradication regimen is most appropriate?
The Australian first-line H. pylori triple therapy is a proton pump inhibitor (PPI) plus amoxicillin plus clarithromycin, taken together for the full course.
That gives PPI + clarithromycin + metronidazole, which keeps a PPI plus two antibiotics and is the correct option here (option B).
Option C (PPI alone) heals and prevents relapse only while it is continued and does not eradicate the organism; option D drops the PPI, which is needed for acid suppression and to support eradication.
The trap: Reaching for the standard first-line PPI + amoxicillin + clarithromycin out of habit. That regimen is correct for most patients, but here the penicillin allergy rules out amoxicillin, so it is swapped for metronidazole. Note also that eradication is confirmed by testing negative at least 4 weeks after therapy and at least 2 weeks after stopping the PPI, to avoid a false negative. classic slip!
One exam decides 50% of your grade. See the official unit outline for hurdle requirements. This whole page is built around that.
Overview
What 9003 is, and where it sits
Clinical Therapeutics 1 (9003) is the University of Canberra Bachelor of Pharmacy unit where the pharmacology and physiology you have learned start to become clinical decisions. It is co-taught with the Master of Pharmacy version (9400), runs over Semester 1 on the Bruce campus, and is built around six disease modules: an introduction to evidence-based therapeutics, gastrointestinal disorders (peptic ulcer disease), cardiovascular disorders, endocrine disorders (diabetes and dyslipidaemia), renal disorders, and respiratory disorders. For each disease the unit works through a fixed nine-point frame: epidemiology, clinical presentation, aetiology and risk factors, pathophysiology, patient impact, diagnostic methods, non-drug management, drug management (monitoring, safety and efficacy), and the role of complementary therapies.
The unit is deliberately applied. Alongside lectures and tutorials it includes a compulsory hospital placement (North Canberra Hospital for BPharm students, scheduled on Wednesday afternoons, subject to change) with a placement induction workshop that all students must attend in Week 1. Practice quizzes accompany every learning module to help you self-check against the learning outcomes, but they do not count toward the final grade. Readings are drawn from clinical references such as Chisholm-Burns, Walker and Whittlesea, the Australian Medicines Handbook (AMH) and Therapeutic Guidelines (eTG), supplemented by primary literature on each condition.
What makes 9003 demanding is breadth plus depth: you have to hold a large amount of drug detail (statins, antihypertensives, antiplatelets and anticoagulants, oral antidiabetics and insulins, proton pump inhibitors and H. pylori regimens) and still reason about which therapy fits a given patient, how to monitor it, and what can go wrong. The reward for that effort is direct: this is the unit that turns a pharmacy student into someone who can recommend and justify a therapeutic plan.
Official outline: canberra.edu.au · 9003 outline. Always treat the official outline and the exam timetable as authoritative.
Difficulty & time commitment
Is 9003 hard, and how much time does it take?
9003 is manageable if you keep a weekly rhythm and treat the back half as the main event. Across student reviews the pattern is consistent: it starts gently and steepens, and the heaviest assessment is the part that separates grades.
The difficulty curve and the assessment weighting point the same way: the back half is harder and worth more. Front-loading effort there is the highest-return decision in the unit.
Is this unit for you
Who tends to do well, and who tends to struggle
You will likely do well if
- You connect mechanism to management: you can move from how a drug works (a statin, a PPI, an oral antidiabetic) to when and why you would actually use it in a patient.
- You build a one-page summary per disease using the nine-point frame (epidemiology, presentation, aetiology, pathophysiology, impact, diagnosis, non-drug management, drug management with monitoring and safety, complementary therapies) and keep it current with AMH and eTG.
- You attempt every module practice quiz after the lectures and readings and use the wrong answers to find the gaps in your reasoning, even though the quizzes do not count.
- You treat the hospital placement as part of the learning, not a box to tick, and link what you see on the ward back to the therapeutic principles from lectures.
You may struggle if
- You try to memorise drug lists without understanding place in therapy, monitoring and safety, which is exactly what the applied questions test.
- You let the large cardiovascular module (hypertension, dyslipidaemia, ACS, stroke and TIA, thrombosis, spread across several weeks) pile up unreviewed.
- You skip the practice quizzes because they are not graded, and so lose the cheapest feedback on whether your reasoning is right.
- You miss or under-prepare for the compulsory placement and induction requirements, which are mandatory parts of the unit.
- For each disease, be able to justify first-line therapy and the main alternatives out loud, including monitoring and the key safety issues, the way the H. pylori example swaps amoxicillin for metronidazole in penicillin allergy.
- Anchor everything to current Australian guidance: the 2023 Australian CVD risk guideline for absolute risk, eTG and AMH for regimens, and know how renal function (GFR/CKD-EPI) changes dosing.
- Practise applying the nine-point frame cold to a new patient scenario so you can reason rather than recall under exam pressure.
- Use the primary-literature readings to add depth (the postgraduate 'future therapies' tasks are a good template), so your answers explain why a therapy is chosen, not just that it is.
Syllabus
The 6 topics, module by module
The exam-weight marker on each topic shows where the marks concentrate. The amber topics carry the highest exam weight.
M1 · Introduction to clinical therapeutics
Intro module + tutorialsEvidence-based medicine and its pioneers (David Sackett), the core epidemiology vocabulary (incidence proportion, incidence, prevalence, aetiology, pathophysiology), how to read therapeutic guidelines, and the placement induction and hospital requirements.
M2 · Gastrointestinal disorders (peptic ulcer disease)
Chisholm-Burns Ch 18; Walker & Whittlesea Ch 12Distinguishing Helicobacter pylori ulcers from NSAID-induced ulcers by risk factors, pathogenesis and course; H. pylori eradication regimens (PPI plus amoxicillin plus clarithromycin first-line in Australia) and the penicillin-allergic alternative; PPI long-term safety; managing high-risk NSAID users.
M3 · Cardiovascular disorders
Australian CVD risk guideline (2023); Hypertension and CAD readingsThe largest module: hypertension, dyslipidaemia, coronary artery disease and acute coronary syndrome, stroke and TIA, and thrombosis. Absolute CVD risk assessment, statins and other lipid-lowering agents, antihypertensives, antiplatelet and anticoagulant therapy, and reversal of non-vitamin-K oral anticoagulants.
M4 · Endocrine disorders
Diabetes and dyslipidaemia learning objectivesType 1, type 2 and gestational diabetes; screening and diagnostic criteria; glycaemic targets and the consequences of uncontrolled diabetes including DKA and euglycaemic ketoacidosis; comparing oral antidiabetic agents by mechanism and place in therapy; selecting insulin by onset, peak and duration.
M5 · Renal disorders
Renal module + GFR (CKD-EPI) estimationChronic kidney disease and urinary tract infection across the nine-point frame, estimating renal function with the CKD-EPI GFR calculator, and the dosing and safety implications of impaired renal function for commonly used medicines.
M6 · Respiratory disorders
Respiratory moduleTherapeutics of common respiratory conditions across the same nine-point frame: presentation, pathophysiology, non-drug and drug management, and monitoring for safety and efficacy.
How it's assessed
Assessment structure
| Component | Weight | Format & timing |
|---|---|---|
| Hospital placement and induction | 20% | Compulsory North Canberra Hospital placement (BPharm), scheduled on Wednesday afternoons, plus a placement induction workshop all students must attend in Week 1. Attendance and completion of the requirements are mandatory. Induction workshop Week 1 (Monday); placements through the semester (some students scheduled in winter or Semester 2). Compulsory: you must attend the sessions and complete the requirements. |
| Coursework and module tasks | 30% | Module-based applied therapeutics work assessing the nine-point disease frame across the six modules. The practice quizzes on Canvas are for self-check only and do not count toward the grade. Across the semester. See the official unit outline for the exact task breakdown. |
| Final examination | 50% | End-of-semester examination covering the six disease modules and the applied therapeutic reasoning developed across the unit. Formal examination period. See the official unit outline for hurdle requirements. |
- Confirm the exact weights, components and any hurdle requirements against the official UC unit outline (9003 UG: https://www.canberra.edu.au/unit-outline/231833). The weighting shown here is an indicative split for a clinical-placement therapeutics unit; the placement is explicitly compulsory.
- Confirm the final-exam structure against the official unit outline. The unit assesses applied clinical reasoning across six disease modules, so expect questions that ask you to justify therapeutic choices, monitoring and safety, not pure recall.
- Calculator policy: A calculator may be needed for dosing and renal-function (GFR/CKD-EPI) estimation; confirm the permitted calculator against the unit outline and exam instructions.
This is an exam-cram unit. With the exams at 50% of the grade and the final examination alone at 50%, your result is overwhelmingly decided by how well you perform under time pressure. See the official unit outline for hurdle requirements.
Final exam timing: approx Nov 2026 (S2 examination period; this unit runs in S1, confirm the actual exam date and period against the official UC exam timetable). Confirm the exact date and venue on the official exam timetable.
How to actually pass it
A weekly rhythm, two checklists, and the traps to avoid
The unit rewards consistency over cramming, and practice over re-reading. Here is the loop that works, then what to have nailed before each exam.
The weekly loop
Before the mid-semester checklist
- Lock down Module 1 vocabulary (incidence proportion versus incidence, aetiology, pathophysiology, evidence-based medicine) and the GI module (H. pylori versus NSAID ulcers, first-line eradication and the penicillin-allergy alternative, PPI long-term safety).
- Start the cardiovascular module early: absolute CVD risk assessment, statins and lipid lowering, and antihypertensive choices, since it is the largest module and spans several weeks.
- Make sure all placement induction and form requirements are complete on time.
- Build one summary sheet per disease in the nine-point frame and keep it current with AMH and eTG.
Before the final heaviest topics
- Be able to apply the nine-point frame to any of the six disease areas (GI, cardiovascular, endocrine, renal, respiratory) from a blank page.
- Drill the high-yield therapeutic decisions: H. pylori eradication and its allergy variant, statin and antihypertensive selection and monitoring, oral antidiabetic and insulin choice, and dose adjustment in renal impairment using GFR/CKD-EPI.
- Practise justifying therapy choices in writing, including monitoring and safety, because the unit rewards applied reasoning over recall.
- Re-test yourself with the module practice quizzes under time pressure and review every miss.
The mistakes that cost marks
Memorising drugs without place in therapy. The unit assesses applied reasoning: which therapy for this patient, how to monitor it and what can go wrong. A list of drug names without the when, why, monitoring and safety will not answer the questions.
Letting the cardiovascular module pile up. Module 3 (hypertension, dyslipidaemia, coronary artery disease and ACS, stroke and TIA, thrombosis) is the largest and is spread across several weeks. Leaving it unreviewed creates a backlog that is hard to clear before the exam.
Skipping the ungraded practice quizzes. The module quizzes do not count toward the grade, so it is tempting to skip them. They are the cheapest, fastest feedback on whether your therapeutic reasoning is actually correct, and skipping them hides your gaps until the exam.
Under-preparing for the compulsory placement. The hospital placement and its Week 1 induction are mandatory, with attendance and form requirements. Treating them casually risks both the requirement and the chance to connect ward practice to the therapeutic principles the unit is testing.
Teaching team
Who teaches 9003
The bios below are factual. The star ratings are not ours: they are impressions from students who have taken the unit, so you can hear from people who sat in the lectures.
Mark Naunton
Professor of Pharmacy in the Faculty of Health, University of Canberra, and convener of Clinical Therapeutics 1, which he co-teaches across the Bachelor and Master of Pharmacy cohorts.
Teaching team as listed in the unit materials reviewed. AskSia does not rate lecturers; star ratings are submitted by students who have taken 9003.
Where it fits
Prerequisites, related units & why it matters
9003 is a clinical-reasoning unit in the Bachelor of Pharmacy and assumes the pharmacology and physiology covered earlier in the degree. It is co-taught with 9400 (Clinical Therapeutics 1 G) for Master of Pharmacy students. Confirm formal prerequisites and the unit's placement in your course map against the official UC unit outline.
Your 9003 study toolkit
Study the unit with Sia, not just read about it
Each tool already knows 9003: your syllabus, your texts, and where the marks are. Grouped by how you study, from first contact to exam week.
FAQ
Frequently asked questions
What is 9003 Clinical Therapeutics 1 about?
It is the University of Canberra Bachelor of Pharmacy unit that turns pharmacology and physiology into clinical decisions. It works through six disease modules (introduction and evidence-based therapeutics, gastrointestinal, cardiovascular, endocrine, renal and respiratory disorders), and for each disease it applies a fixed nine-point frame from epidemiology and pathophysiology through to drug management, monitoring and safety. It also includes a compulsory hospital placement.
Is 9003 hard?
It is one of the more demanding pharmacy units because it combines breadth and depth. You have to hold a large volume of drug detail across six disease areas and still reason about which therapy fits a given patient, how to monitor it and what can go wrong, then apply that on a hospital placement. It is very manageable with steady weekly work and active use of the practice quizzes, but it rewards understanding over memorisation.
Do the practice quizzes count toward my grade?
No. The Canvas practice quizzes for each module are designed to help you meet the learning outcomes and to self-check your understanding, but they do not count toward your final grade in Clinical Therapeutics 1. It is recommended you attempt them after completing the lectures, readings and tutorials for that module.
Is the hospital placement compulsory?
Yes. The placement and its induction are compulsory. There is a placement induction workshop in Week 1 that all students must attend, and BPharm North Canberra Hospital placements are scheduled on Wednesday afternoons (subject to change). Some students may have placements scheduled in winter semester or Semester 2. Attendance and completion of the requirements are mandatory.
How is 9003 different from 9400?
9003 is the Bachelor of Pharmacy version and 9400 is the Master of Pharmacy version (Clinical Therapeutics 1 G). They are co-taught and share the same lectures, modules and disease frame, with postgraduate students given additional depth tasks, for example identifying and discussing one or more future therapies for a condition such as hypercholesterolaemia.
What should I read for this unit?
Core clinical references include Chisholm-Burns and Walker and Whittlesea for the disease chapters, plus the Australian Medicines Handbook (AMH) and Therapeutic Guidelines (eTG) for current Australian therapeutic advice. Each module also lists primary-literature readings (for example the 2023 Australian CVD risk guideline and condition-specific review articles). Confirm the current reading list on your UCLearn (Canvas) site.
Study 9003 with Sia
Work through cardiovascular disorders, endocrine disorders, renal disorders and the rest of the unit with a tutor that knows it and quizzes you on the topics the assessments weight most heavily.
Start studying with Sia